- active covid-19 disease; - confirmed prior covid-19 disease; - current fever, cough, shortness of breath; - contraindication or hypersensitivity to chloroquine or hydroxychloroquine ad hypersensitivity to 4-aminoquinoline compounds; - pregnancy; - lactation; - prior retinal eye disease; - known chronic kidney disease, stage 4 or 5 or dialysis; - known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency ; - weight <40 kg; - current use of chloroquine,hydroxychloroquine or cardiac medicines like flecainide, amiodarone, digoxin, procainamide, or propafenone; - current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen or methotrexate; - current use of medications causing qt interval prolongation like: macrolides,antipsychotics,quinolones,antihistamines,ssris,tricyclic antidepressants, antifungals; - recent myocardial infarction; - history of epilepsy

- active covid-19 disease; - confirmed prior covid-19 disease; - current fever, cough, shortness of breath; - contraindication or hypersensitivity to chloroquine or hydroxychloroquine ad hypersensitivity to 4-aminoquinoline compounds; - pregnancy; - lactation; - prior retinal eye disease; - known chronic kidney disease, stage 4 or 5 or dialysis; - known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency ; - weight <40 kg; - current use of chloroquine,hydroxychloroquine or cardiac medicines like flecainide, amiodarone, digoxin, procainamide, or propafenone; - current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen or methotrexate; - current use of medications causing qt interval prolongation like: macrolides,antipsychotics,quinolones,antihistamines,ssris,tricyclic antidepressants, antifungals; - recent myocardial infarction; - history of epilepsy